title: Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.
abstract: To determine whether rifampin reduces concentrations of trimethoprim (TMP) and sulfamethoxazole (SMX) in serum of human immunodeficiency virus (HIV)-infected persons, levels of these agents were determined by high-performance liquid chromatography before and after more than 12 days of standard antituberculosis treatment for 10 patients who had been taking one double-strength tablet of co-trimoxazole once daily for more than 1 month. Statistically significant, 47 and 23% decreases in TMP and SMX mean areas under the concentration-time curve from 0 to 24 h (AUC(0-24)), respectively, were observed after administration of rifampin. N-Acetyl-SMX profiles without and with rifampin were similar. The steady-state AUC(0-24) metabolite/parent drug ratio increased by 32% with rifampin administration. Our study shows that rifampin reduces profiles of TMP and SMX in serum of HIV-infected patients.
authors.affiliation: Infectious Disease Service, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain. eribera@hg.vhebron.es
authors.forename: E
authors.initials: E
authors.lastname: Ribera
authors.forename: L
authors.initials: L
authors.lastname: Pou
authors.forename: A
authors.initials: A
authors.lastname: Fernandez-Sola
authors.forename: F
authors.initials: F
authors.lastname: Campos
authors.forename: R M
authors.initials: RM
authors.lastname: Lopez
authors.forename: I
authors.initials: I
authors.lastname: Ocaña
authors.forename: I
authors.initials: I
authors.lastname: Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Pahissa
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics*; D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008297:Male; D012293:Rifampin / Q000009:adverse effects*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D012293:Rifampin